News Releases

Fibrocell Science, Inc. Announces Recognition for LAVIV™ (azficel-T) at The 2012 Cell & Gene Therapy Forum, Washington, D.C.

Posted at Feb 01, 2012 | Posted in  Press Releases |

LAVIV™ named the #3 top story of 2011 in cell & gene therapy and regenerative medicine— EXTON, Pa., January 30, 2012 – Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announces that the June 2011 FDA approval of LAVIV™ (azficel-T)Read more


Fibrocell Science, Inc. to Present at the 5th Annual OneMedForum San Francisco 2012

Posted at Jan 04, 2012 | Posted in  Press Releases |

EXTON, Pa., January 4, 2012 – Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will be presenting at the 5th Annual OneMedForum San Francisco 2012 to be held on JanuaryRead more


Fibrocell Science, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference

Posted at Dec 01, 2011 | Posted in  Press Releases |

EXTON, Pa., Dec 01, 2011 – Fibrocell Science, Inc. (OTCBB:FCSC.OB), a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will be presenting at the Oppenheimer 22nd Annual Healthcare Conference to be held on December 13-14, 2011Read more


Fibrocell Science, Inc. to Present at the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics and Metabolic Disorders Conference

Posted at Nov 23, 2011 | Posted in  Press Releases |

EXTON, Pa., November 23, 2011 – Fibrocell Science, Inc. (OTCBB:FCSC.OB), an biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will be presenting at the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics and Metabolic Disorders Conference to beRead more


Fibrocell Science, Inc. to Host Investor Conference Call to Discuss Third Quarter 2011 Business Update

Posted at Nov 08, 2011 | Posted in  Press Releases |

EXTON, Pa., November 08, 2011 – Fibrocell Science, Inc. (OTCBB:FCSC.OB), an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will host an investor conference call to discuss Fibrocell’s business update for the third quarter ended SeptemberRead more